

# Lin Chang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/861331/publications.pdf>

Version: 2024-02-01

231  
papers

14,169  
citations

18465

62  
h-index

22147

113  
g-index

240  
all docs

240  
docs citations

240  
times ranked

9307  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bowel Disorders. <i>Gastroenterology</i> , 2016, 150, 1393-1407.e5.	0.6	1,912
2	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. <i>Gastroenterology</i> , 2016, 150, 1481-1491.	0.6	400
3	V. Stress and irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, G519-G524.	1.6	362
4	Gender, Age, Society, Culture, and the Patient's Perspective in the Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1435-1446.	0.6	320
5	Cerebral Activation in Patients With Irritable Bowel Syndrome and Control Subjects During Rectosigmoid Stimulation. <i>Psychosomatic Medicine</i> , 2001, 63, 365-375.	1.3	291
6	Review article: epidemiology and quality of life in functional gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 31-39.	1.9	288
7	Gender differences in irritable bowel syndrome. <i>Gastroenterology</i> , 2002, 123, 1686-1701.	0.6	268
8	Sex-related differences in IBS patients: central processing of visceral stimuli. <i>Gastroenterology</i> , 2003, 124, 1738-1747.	0.6	264
9	Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. <i>Pain</i> , 2005, 115, 398-409.	2.0	251
10	Association Between Early Adverse Life Events and Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 385-390.e3.	2.4	251
11	A Comparison of Visceral and Somatic Pain Processing in the Human Brainstem Using Functional Magnetic Resonance Imaging. <i>Journal of Neuroscience</i> , 2005, 25, 7333-7341.	1.7	234
12	Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17095.	18.1	203
13	The Central Role of Gastrointestinal-Specific Anxiety in Irritable Bowel Syndrome: Further Validation of the Visceral Sensitivity Index. <i>Psychosomatic Medicine</i> , 2007, 69, 89-98.	1.3	196
14	The Role of Stress on Physiologic Responses and Clinical Symptoms in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2011, 140, 761-765.e5.	0.6	194
15	Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. <i>American Journal of Gastroenterology</i> , 2003, 98, 135-143.	0.2	192
16	Gender-related differences in IBS symptoms. <i>American Journal of Gastroenterology</i> , 2001, 96, 2184-2193.	0.2	190
17	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales. <i>American Journal of Gastroenterology</i> , 2014, 109, 1804-1814.	0.2	190
18	Longitudinal Change in Perceptual and Brain Activation Response to Visceral Stimuli in Irritable Bowel Syndrome Patients. <i>Gastroenterology</i> , 2006, 131, 352-365.	0.6	175

#	ARTICLE	IF	CITATIONS
19	Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. <i>Pain</i> , 2000, 84, 297-307.	2.0	174
20	Childhood Trauma Is Associated With Hypothalamic-Pituitary-Adrenal Axis Responsiveness in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2009, 137, 1954-1962.	0.6	167
21	Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2001, 96, 3341-3347.	0.2	163
22	Clinical Determinants of Health-Related Quality of Life in Patients With Irritable Bowel Syndrome. <i>Archives of Internal Medicine</i> , 2004, 164, 1773.	4.3	158
23	Gender differences in regional brain response to visceral pressure in IBS patients. <i>European Journal of Pain</i> , 2000, 4, 157-172.	1.4	157
24	A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 1803-1812.	0.2	156
25	Is Irritable Bowel Syndrome a Diagnosis of Exclusion? A Survey of Primary Care Providers, Gastroenterologists, and IBS Experts. <i>American Journal of Gastroenterology</i> , 2010, 105, 848-858.	0.2	153
26	Incidence of Ischemic Colitis and Serious Complications of Constipation Among Patients Using Alosetron: Systematic Review of Clinical Trials and Post-Marketing Surveillance Data. <i>American Journal of Gastroenterology</i> , 2006, 101, 1069-1079.	0.2	151
27	A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. <i>Gut</i> , 2005, 54, 1707-1713.	6.1	150
28	Functional GI disorders: from animal models to drug development. <i>Gut</i> , 2008, 57, 384-404.	6.1	140
29	Prevalence of irritable bowel syndrome among university students. <i>Journal of Psychosomatic Research</i> , 2003, 55, 501-505.	1.2	137
30	Serum and Colonic Mucosal Immune Markers in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2012, 107, 262-272.	0.2	131
31	Condition-specific deactivation of brain regions by 5-HT <sub>3</sub> receptor antagonist Alosetron. <i>Gastroenterology</i> , 2002, 123, 969-977.	0.6	128
32	The Effect of Life Stress on Symptoms of Heartburn. <i>Psychosomatic Medicine</i> , 2004, 66, 426-434.	1.3	127
33	Sex specific alterations in autonomic function among patients with irritable bowel syndrome. <i>Gut</i> , 2005, 54, 1396-1401.	6.1	127
34	A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS. <i>American Journal of Gastroenterology</i> , 2005, 100, 115-123.	0.2	125
35	Preoperative Versus Postoperative Endoscopic Retrograde Cholangiopancreatography in Mild to Moderate Gallstone Pancreatitis. <i>Annals of Surgery</i> , 2000, 231, 82.	2.1	121
36	Cortical processing of visceral and somatic stimulation: Differentiating pain intensity from unpleasantness. <i>Neuroscience</i> , 2005, 133, 533-542.	1.1	120

#	ARTICLE	IF	CITATIONS
37	Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. <i>Gut</i> , 2018, 67, 263-270.	6.1	120
38	Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome?. <i>Gender Medicine</i> , 2009, 6, 152-167.	1.4	116
39	Characterization of the Alternating Bowel Habit Subtype in Patients with Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2005, 100, 896-904.	0.2	113
40	American Gastroenterological Association Institute Technical Review on the Pharmacological Management of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2014, 147, 1149-1172.e2.	0.6	113
41	Predictors of Patient-Assessed Illness Severity in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2008, 103, 2536-2543.	0.2	112
42	MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. <i>Gastroenterology</i> , 2015, 149, 981-992.e11.	0.6	112
43	Symptom Differences in Moderate to Severe Ibs Patients Based on Predominant Bowel Habit. <i>American Journal of Gastroenterology</i> , 1999, 94, 2929-2935.	0.2	109
44	Brain Responses To Visceral and Somatic Stimuli in Patients With Irritable Bowel Syndrome With and Without Fibromyalgia. <i>American Journal of Gastroenterology</i> , 2003, 98, 1354-1361.	0.2	106
45	A Focus Group Assessment of Patient Perspectives on Irritable Bowel Syndrome and Illness Severity. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1532-1541.	1.1	102
46	Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006, 291, R277-R284.	0.9	97
47	Diagnosis and management of IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 565-581.	8.2	96
48	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021, 53, 1543-1552.	9.4	96
49	Sex-based differences in gastrointestinal pain. <i>European Journal of Pain</i> , 2004, 8, 451-463.	1.4	93
50	Bacterial Overgrowth and Irritable Bowel Syndrome: Unifying Hypothesis or a Spurious Consequence of Proton Pump Inhibitors?. <i>American Journal of Gastroenterology</i> , 2008, 103, 2972-2976.	0.2	91
51	Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1161-1168.	1.9	90
52	Gallstone Pancreatitis: A Prospective Study on the Incidence of Cholangitis and Clinical Predictors of Retained Common Bile Duct Stones. <i>American Journal of Gastroenterology</i> , 1998, 93, 527-531.	0.2	89
53	Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1252-1260.	1.6	88
54	Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. <i>American Journal of Gastroenterology</i> , 2002, 97, 2803-2811.	0.2	86

#	ARTICLE	IF	CITATIONS
55	Impact of Sex and Gender on Irritable Bowel Syndrome. <i>Biological Research for Nursing</i> , 2003, 5, 56-65.	1.0	85
56	Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences. <i>American Journal of Gastroenterology</i> , 2010, 105, 866-875.	0.2	77
57	Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000134.	1.1	77
58	Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome?. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 892-899.	0.5	74
59	Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 152-156.	0.2	71
60	Gastrointestinal and Psychological Mediators of Health-Related Quality of Life in IBS and IBD: A Structural Equation Modeling Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 451-459.	0.2	71
61	Basic Pathophysiologic Mechanisms in Irritable Bowel Syndrome. <i>Digestive Diseases</i> , 2001, 19, 212-218.	0.8	69
62	Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles. <i>Gastroenterology</i> , 2008, 135, 1877-1891.	0.6	65
63	Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1673-1676.	2.4	64
64	Attentional modulation of visceral and somatic pain. <i>Neurogastroenterology and Motility</i> , 2007, 19, 569-577.	1.6	63
65	Developing Valid and Reliable Health Utilities in Irritable Bowel Syndrome: Results From the IBS PROOF Cohort. <i>American Journal of Gastroenterology</i> , 2009, 104, 1984-1991.	0.2	60
66	Activation of pruritogenic TGR5, MrgprA3, and MrgprC11 on colon-innervating afferents induces visceral hypersensitivity. <i>JCI Insight</i> , 2019, 4, .	2.3	59
67	Brain Responses to Visceral and Somatic Stimuli in Irritable Bowel Syndrome: a Central Nervous System Disorder?. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 271-279.	1.0	58
68	A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship: A Rome Foundation Working Team Report. <i>Gastroenterology</i> , 2021, 161, 1670-1688.e7.	0.6	56
69	Functional Bowel Disorders: A Roadmap to Guide the Next Generation of Research. <i>Gastroenterology</i> , 2018, 154, 723-735.	0.6	55
70	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2018, 155, 168-179.	0.6	55
71	Enhanced preattentive central nervous system reactivity in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2002, 97, 2791-2797.	0.2	54
72	Impact of irritable bowel syndrome on patients' lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 411-420.	0.8	52

#	ARTICLE	IF	CITATIONS
73	Expression of the Bitter Taste Receptor, T2R38, in Enteroendocrine Cells of the Colonic Mucosa of Overweight/Obese vs. Lean Subjects. <i>PLoS ONE</i> , 2016, 11, e0147468.	1.1	52
74	Irritable Bowel Syndrome: Current Approach to Symptoms, Evaluation, and Treatment. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 665-685.	1.0	48
75	A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 344-357.	1.4	47
76	Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1114-1122.	1.9	47
77	Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2017, 112, 892-899.	0.2	47
78	GERD Symptoms in the General Population: Prevalence and Severity Versus Care-Seeking Patients. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2488-2496.	1.1	45
79	AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. <i>Gastroenterology</i> , 2022, 163, 118-136.	0.6	45
80	New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments. <i>Current Gastroenterology Reports</i> , 2005, 7, 272-279.	1.1	44
81	The effect of sex and irritable bowel syndrome on HPA axis response and peripheral glucocorticoid receptor expression. <i>Psychoneuroendocrinology</i> , 2016, 69, 67-76.	1.3	43
82	Early adverse life events are associated with altered brain network architecture in a sex- dependent manner. <i>Neurobiology of Stress</i> , 2017, 7, 16-26.	1.9	43
83	AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. <i>Gastroenterology</i> , 2022, 163, 137-151.	0.6	43
84	The Association of Functional Gastrointestinal Disorders and Fibromyalgia. <i>The European Journal of Surgery</i> , 1998, 164, 32-36.	1.0	41
85	Computer-Generated Vs. Physician-Documented History of Present Illness (HPI): Results of a Blinded Comparison. <i>American Journal of Gastroenterology</i> , 2015, 110, 170-179.	0.2	41
86	Irritable bowel syndrome patients have <i>SCN5A</i> channelopathies that lead to decreased $Na^{+}$ current and mechanosensitivity. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G494-G503.	1.6	40
87	Racial Differences in the Impact of Irritable Bowel Syndrome on Health-Related Quality of Life. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 782-789.	1.1	39
88	Increased Acoustic Startle Responses in IBS Patients During Abdominal and Nonabdominal Threat. <i>Psychosomatic Medicine</i> , 2008, 70, 920-927.	1.3	39
89	Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13155.	1.6	39
90	Morphological brain measures of cortico-limbic inhibition related to resilience. <i>Journal of Neuroscience Research</i> , 2017, 95, 1760-1775.	1.3	38

#	ARTICLE	IF	CITATIONS
91	AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review. <i>Gastroenterology</i> , 2022, 162, 1737-1745.e5.	0.6	38
92	Autonomic response to a visceral stressor is dysregulated in irritable bowel syndrome and correlates with duration of disease. <i>Neurogastroenterology and Motility</i> , 2013, 25, e650-9.	1.6	37
93	Differences in Gastrointestinal Symptoms According to Gender in Rome II Positive IBS and Dyspepsia in a Latin American Population. <i>American Journal of Gastroenterology</i> , 2010, 105, 925-932.	0.2	36
94	Diminished Expression of Corticotropin-Releasing Hormone Receptor 2 in Human Colon Cancer Promotes Tumor Growth and Epithelial-to-Mesenchymal Transition via Persistent Interleukin-6/Stat3 Signaling. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 610-630.	2.3	36
95	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1186-1192.	1.1	36
96	Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 253-275.	1.4	36
97	Understanding Gastrointestinal Distress: A Framework for Clinical Practice. <i>American Journal of Gastroenterology</i> , 2011, 106, 380-385.	0.2	34
98	miR-24 Is Elevated in Ulcerative Colitis Patients and Regulates Intestinal Epithelial Barrier Function. <i>American Journal of Pathology</i> , 2019, 189, 1763-1774.	1.9	31
99	Diagnosis and treatment of irritable bowel syndrome: State of the art. <i>Current Gastroenterology Reports</i> , 2005, 7, 249-256.	1.1	30
100	Diagnostic approach to the patient with irritable bowel syndrome. <i>American Journal of Medicine</i> , 1999, 107, 20-26.	0.6	29
101	Characteristics of Acute Pain Attacks in Patients With Irritable Bowel Syndrome Meeting Rome III Criteria. <i>American Journal of Gastroenterology</i> , 2011, 106, 1299-1307.	0.2	29
102	Identification of a Functional TPH1 Polymorphism Associated With Irritable Bowel Syndrome Bowel Habit Subtypes. <i>American Journal of Gastroenterology</i> , 2013, 108, 1766-1774.	0.2	29
103	Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2016, 28, 410-422.	1.6	29
104	Risk and Protective Factors Related to Early Adverse Life Events in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 63-69.	1.1	28
105	Obesity is associated with a distinct brain-gut microbiome signature that connects Prevotella and Bacteroides to the brain's reward center. <i>Gut Microbes</i> , 2022, 14, 2051999.	4.3	28
106	Risk Factors for Abdominal Pain-Related Disorders of Gut-Brain Interaction in Adults and Children: A Systematic Review. <i>Gastroenterology</i> , 2022, 163, 995-1023.e3.	0.6	28
107	Predictors of Health-related Quality of Life in Irritable Bowel Syndrome Patients Compared With Healthy Individuals. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e142-e149.	1.1	27
108	Is There a Difference Between Abdominal Pain and Discomfort in Moderate to Severe IBS Patients?. <i>American Journal of Gastroenterology</i> , 2002, 97, 3131-3138.	0.2	26

#	ARTICLE	IF	CITATIONS
109	Interactions of early adversity with stress-related gene polymorphisms impact regional brain structure in females. <i>Brain Structure and Function</i> , 2016, 221, 1667-1679.	1.2	26
110	The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p Are Downregulated in Irritable Bowel Syndrome and Are Associated With Barrier Function and MAPK Signaling. <i>Gastroenterology</i> , 2021, 160, 2409-2422.e19.	0.6	26
111	A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. <i>Gastroenterology</i> , 2000, 118, A846.	0.6	25
112	The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1302-1312.	1.9	25
113	Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database. <i>American Journal of Gastroenterology</i> , 2014, 109, 234-248.	0.2	25
114	Î²-opioid receptor, Î²-endorphin, and cannabinoid receptor 2 are increased in the colonic mucosa of irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13688.	1.6	25
115	Construct Validity of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2014, 66, 1725-1730.	1.5	24
116	Sex-Related Differences in GI Disorders. <i>Handbook of Experimental Pharmacology</i> , 2017, 239, 177-192.	0.9	23
117	Epigenetic Mechanisms in Irritable Bowel Syndrome. <i>Frontiers in Psychiatry</i> , 2020, 11, 805.	1.3	23
118	Towards an integrative model of irritable bowel syndrome. <i>Progress in Brain Research</i> , 2000, 122, 413-423.	0.9	22
119	Neuroendocrine and Neuroimmune Markers in IBS: Pathophysiological Role or Epiphenomenon?. <i>Gastroenterology</i> , 2006, 130, 596-600.	0.6	22
120	Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1576-1584.	0.9	22
121	Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID. <i>American Journal of Gastroenterology</i> , 2010, 105, 722-730.	0.2	21
122	Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13003.	1.6	21
123	Negative Events During Adulthood Are Associated With Symptom Severity and Altered Stress Response in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2245-2252.	2.4	21
124	Computer versus physician identification of gastrointestinal alarm features. <i>International Journal of Medical Informatics</i> , 2015, 84, 1111-1117.	1.6	20
125	Effect of Exclusion Diets on Symptom Severity and the Gut Microbiota in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e465-e483.	2.4	20
126	Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. <i>American Journal of Gastroenterology</i> , 2021, 116, 1929-1937.	0.2	19



#	ARTICLE	IF	CITATIONS
127	Gene expression profiles in peripheral blood mononuclear cells correlate with salience network activity in chronic visceral pain: A pilot study. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13027.	1.6	18
128	Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 689-699.	1.4	18
129	Sigmoid colon mucosal gene expression supports alterations of neuronal signaling in irritable bowel syndrome with constipation. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G140-G157.	1.6	18
130	The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 2541-2550.e1.	2.4	18
131	Catecholaminergic Gene Polymorphisms Are Associated with GI Symptoms and Morphological Brain Changes in Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2015, 10, e0135910.	1.1	18
132	Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 748-757.	0.2	18
133	Analysis of brain networks and fecal metabolites reveals brain-gut alterations in premenopausal females with irritable bowel syndrome. <i>Translational Psychiatry</i> , 2020, 10, 367.	2.4	17
134	Postmenopausal women with irritable bowel syndrome (IBS) have more severe symptoms than premenopausal women with IBS. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13913.	1.6	17
135	Small intestinal immunopathology and GI-associated antibody formation in hereditary alpha-tryptasemia. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 813-821.e7.	1.5	17
136	New Treatments for Irritable Bowel Syndrome in Women. <i>Women's Health</i> , 2008, 4, 605-622.	0.7	16
137	Emerging Pharmacological Therapies for the Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 223-243.	1.0	16
138	Functional Bowel Disorders. <i>Gastroenterology</i> , 2018, 155, 1-4.	0.6	16
139	Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. <i>American Journal of Gastroenterology</i> , 2021, 116, 1601-1611.	0.2	15
140	Admission factors can predict the need for ICU monitoring in gallstone pancreatitis. <i>American Surgeon</i> , 1996, 62, 815-9.	0.4	15
141	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1836-1844.	1.1	14
142	Latest Insights on the Pathogenesis of Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 505-522.	1.0	14
143	Novel techniques to study visceral hypersensitivity in irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , 2008, 10, 369-378.	1.1	13
144	A cross-cultural investigation of attachment style, catastrophizing, negative pain beliefs, and symptom severity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2015, 27, 490-500.	1.6	13

#	ARTICLE	IF	CITATIONS
145	Unconscious Bias in Peer Review. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 419-420.	2.4	13
146	Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 291-305.	1.4	12
147	Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984129.	1.4	12
148	Plasma Corticotropin-Releasing Factor Receptors and B7-2+ Extracellular Vesicles in Blood Correlate with Irritable Bowel Syndrome Disease Severity. <i>Cells</i> , 2019, 8, 101.	1.8	12
149	Does mind-body medicine have a role in gastroenterology?. <i>Current Opinion in Gastroenterology</i> , 1997, 13, 1-4.	1.0	11
150	Using the Rome IV Criteria to Help Manage the Complex IBS Patient. <i>American Journal of Gastroenterology</i> , 2018, 113, 453-456.	0.2	11
151	Increasing Rates of Opioid Prescriptions for Gastrointestinal Diseases in the United States. <i>American Journal of Gastroenterology</i> , 2021, 116, 796-807.	0.2	11
152	Brain-gut interactions: implications for newer therapy. <i>The European Journal of Surgery</i> , 2003, 164, 50-55.	1.0	9
153	Benefits and Pitfalls of Change From Rome III to Rome IV Criteria for Irritable Bowel Syndrome and Fecal Incontinence. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 297-299.	2.4	9
154	Importance of trauma-related fear in patients with irritable bowel syndrome and early adverse life events. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13896.	1.6	9
155	An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-12.	0.2	9
156	Clostridial bacteremia: implications for the surgeon. <i>American Surgeon</i> , 1991, 57, 388-93.	0.4	9
157	Early computed tomography is rarely necessary in gallstone pancreatitis. <i>American Surgeon</i> , 1997, 63, 904-7.	0.4	9
158	Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response. <i>Psychoneuroendocrinology</i> , 2016, 73, 133-141.	1.3	8
159	A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 281-291.	1.9	8
160	Evidence for decreased activation of central fear circuits by expected aversive visceral stimuli in IBS patients. <i>Gastroenterology</i> , 2000, 118, A137.	0.6	7
161	Irritable bowel syndrome. <i>Current Treatment Options in Gastroenterology</i> , 2002, 5, 267-278.	0.3	7
162	Irritable bowel syndrome: new and emerging therapies. <i>Current Opinion in Internal Medicine</i> , 2006, 5, 297-304.	1.5	7

#	ARTICLE	IF	CITATIONS
163	Alosetron: An Effective Treatment for Diarrhea-Predominant Irritable Bowel Syndrome. <i>Women's Health</i> , 2007, 3, 15-27.	0.7	7
164	313 Effects of Rifaximin on Urgency, Bloating, and Abdominal Pain in Patients With IBS-D: A Randomized, Controlled, Repeat Treatment Study. <i>Gastroenterology</i> , 2015, 148, S-69.	0.6	7
165	The Gut Microbiome and Digestive Health – A New Frontier. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 215-217.	2.4	7
166	Opioid Prescription Patterns Among US Gastroenterologists From 2013 to 2017. <i>Gastroenterology</i> , 2020, 158, 776-779.e2.	0.6	7
167	Evolving pathophysiological model of functional gastrointestinal disorders: implications for treatment. <i>The European Journal of Surgery Supplement: = Acta Chirurgica Supplement</i> , 2002, , 3-9.	0.2	7
168	Approaches to the Modulation of Abdominal Pain. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 1999, 13, 66A-70A.	1.8	6
169	Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use. <i>Biological Research for Nursing</i> , 2021, 23, 171-179.	1.0	6
170	The Transition From Rome III to Rome IV Irritable Bowel Syndrome: What We Gain and Lose. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 508-510.	2.4	6
171	How to Approach a Patient with Difficult-to-Treat IBS. <i>Gastroenterology</i> , 2021, 161, 1092-1098.e3.	0.6	6
172	T1026 Measuring IBS Patient Reported Outcomes with a Single Item Numeric Rating Scale: Results from the PROOF Cohort. <i>Gastroenterology</i> , 2008, 134, A-467.	0.6	4
173	Understanding the Multidimensional Nature of Illness Severity as Measured by Patient-Reported Outcome Measures in Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 918-919.	2.4	4
174	Do Patients Understand the Bristol Stool Scale? Results of Cognitive De-Briefing of IBS Patients. <i>Gastroenterology</i> , 2011, 140, S-615.	0.6	4
175	Mo1616 Resilience Is Decreased in Irritable Bowel Syndrome (IBS) and Associated With Poorer Quality of Life and Greater Symptom Severity. <i>Gastroenterology</i> , 2016, 150, S731.	0.6	4
176	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 394-399.e2.	2.3	4
177	1090 - Epigenetic Changes in Blood Cells and Colonic Mucosa are Associated with Irritable Bowel Syndrome (IBS). <i>Gastroenterology</i> , 2018, 154, S-214.	0.6	4
178	Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4140-4148.	1.1	4
179	An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D. <i>Gastroenterology and Hepatology</i> , 2013, 9, 1-24.	0.2	4
180	The visceral sensitivity index: A novel tool for measuring GI symptom-specific anxiety in inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14384.	1.6	4

#	ARTICLE	IF	CITATIONS
181	The role of gender and bowel habit predominance on visceral perception in IBS. <i>Gastroenterology</i> , 2001, 120, A755.	0.6	3
182	Response to Drs Trivedi and Ward. <i>American Journal of Gastroenterology</i> , 2012, 107, 140-141.	0.2	3
183	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, e77-e86.	2.4	3
184	Increased Sleep Disturbances in Irritable Bowel Syndrome (IBS) Patients is Associated with Greater Symptom Severity and Decreased Quality Of Life. <i>Gastroenterology</i> , 2017, 152, S716.	0.6	3
185	Dysregulation of the Long-Noncoding RNA, Chrlos, in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S722.	0.6	3
186	High Opioid Prescribing Profiles Among Gastroenterologists: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	3
187	Differences in rectal mechanoelastic properties according to predominant bowel habit in IBS patients. <i>Gastroenterology</i> , 2000, 118, A667.	0.6	2
188	Ratings of sigmoid but not rectal distensions correlate with IBS symptom severity. <i>Gastroenterology</i> , 2000, 118, A445.	0.6	2
189	Evidence for selective effect of the 5HT3 antagonist alosetron on amygdala and hippocampal activation in IBS patients. <i>Gastroenterology</i> , 2000, 118, A81.	0.6	2
190	The effect of the 5-HT3 receptor antagonist alosetron on regional brain activation in IBS patients is not dependent on activation of nociceptive visceral afferents: A H2150 PET study. <i>Gastroenterology</i> , 2001, 120, A67.	0.6	2
191	Clinical determinants of health-related quality of life in irritable bowel syndrome. <i>Gastroenterology</i> , 2003, 124, A398.	0.6	2
192	Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>American Journal of Gastroenterology</i> , 2015, 110, S761.	0.2	2
193	366 Guanylate Cyclase-C Expression Is Down-Regulated in Colonic Biopsies From Female Irritable Bowel Syndrome Patients With Constipation. <i>Gastroenterology</i> , 2016, 150, S81-S82.	0.6	2
194	Do Proton Pump Inhibitors (PPIs) Predispose to the Development of SIBO in IBS versus Non-IBS Patients?. <i>American Journal of Gastroenterology</i> , 2009, 104, S103-S104.	0.2	2
195	Guanylate Cyclase-C Receptor and Ligand Expression in Colonic Mucosa in Chronic Constipation. <i>American Journal of Gastroenterology</i> , 2014, 109, S540.	0.2	2
196	Gender differences in autonomic activity in IBS. <i>Gastroenterology</i> , 2000, 118, A137.	0.6	1
197	Mo1273 The Association of Early Adverse Life Events and Irritable Bowel Syndrome (IBS) Is Amplified by the Presence of Peritraumatic Fear. <i>Gastroenterology</i> , 2015, 148, S-656-S-657.	0.6	1
198	Impact of Baseline Pain Severity on the Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. <i>American Journal of Gastroenterology</i> , 2016, 111, S254.	0.2	1

#	ARTICLE	IF	CITATIONS
199	Colonic Mucosal Microbiome is Associated with Mucosal MicroRNA Expression in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S40-S41.	0.6	1
200	Expression Profiling of Sigmoid Biopsies in Irritable Bowel Syndrome vs Healthy Controls. <i>Gastroenterology</i> , 2017, 152, S722.	0.6	1
201	Is It Time to Abandon Gastric Emptying in Patients With Symptoms of Gastroparesis and Functional Dyspepsia?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	1
202	Gender-Related Differences in Functional Bowel Disorders. , 2004, , 438-445.		1
203	Is IBS a Predictor of SIBO as Identified by Hydrogen/Methane Breath Testing?. <i>American Journal of Gastroenterology</i> , 2009, 104, S110.	0.2	1
204	Effects of Linaclotide on Abdominal and Bowel Symptoms Over the First Seven Days of Treatment in Patients with Irritable Bowel Syndrome with Constipation. <i>American Journal of Gastroenterology</i> , 2012, 107, S710-S711.	0.2	1
205	Effect of Eluxadoline on Abdominal and Bowel Symptoms Over Time in Phase 3 Clinical Trials in Patients With Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2015, 110, S748.	0.2	1
206	Negative Feedback of the Hypothalamic Pituitary Adrenal (HPA) Axis as Assessed by the Dexamethasone-Corticotropin Releasing Factor (CRF) Test in Irritable Bowel Syndrome (IBS). <i>American Journal of Gastroenterology</i> , 2015, 110, S755-S756.	0.2	1
207	Gender and Other Factors Associated with Endoscopy Volume Among U.S. Gastroenterology Fellows. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2911-2914.e4.	2.4	1
208	Comment on "Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia" L. Chang et al., <i>PAIN</i> 84 (2000) 297-307. <i>Pain</i> , 2001, 91, 404-405.	2.0	0
209	A Functional Promoter Variant in the Tryptophan Hydroxylase 1 Gene is Associated With a Bowel Habit Phenotype in Patients With Irritable Bowel Syndrome (IBS). <i>Gastroenterology</i> , 2011, 140, S-111.	0.6	0
210	Factors Analysis of Bowel Symptoms in IBS: Guidance for Patient Reported Outcome (PRO) Development. <i>Gastroenterology</i> , 2011, 140, S-605-S-606.	0.6	0
211	Treatment of bloating and distension - role of probiotics: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 581-583.	1.9	0
212	Evaluation of the Patient Reported Outcomes Measurement Information System (PROMIS) in Celiac Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, S464.	0.2	0
213	Tu1788 Corticotropin-Releasing Hormone Receptor 1 (CRH-R1) Polymorphisms are Associated With Irritable Bowel Syndrome (IBS) and Acoustic Startle Response (ASR). <i>Gastroenterology</i> , 2016, 150, S946-S947.	0.6	0
214	Tu1794 Functional Pathways Associated With Differential Colonic Mucosal Expression of microRNA and mRNA in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 150, S949.	0.6	0
215	Tu1799 Differences in Cortisol Responses to Hormone Challenge vs. Visceral Stressor in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 150, S950-S951.	0.6	0
216	Tu1803 IBS-Associated SCN5A Mutation G615E Results in a NaV1.5 Channel With Normal Na+ Current Density but Loss of Mechanosensitivity. <i>Gastroenterology</i> , 2016, 150, S952.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Tu1802 Colonic Immune Cells in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2016, 150, S951-S952.	0.6	0
218	Trauma Severity and Lack of Confiding in Others Increases Risk of Having Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S711-S712.	0.6	0
219	Resilience is Associated with Early Life Stress and HPA Axis Response in IBS. <i>Gastroenterology</i> , 2017, 152, S921.	0.6	0
220	Sex-Dependent Alterations of Colonic Epithelial Permeability in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S723.	0.6	0
221	Impact of Rifaximin on Health-Related Quality of Life in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S913.	0.6	0
222	Predictors of Quality of Life in Irritable Bowel Syndrome Compared to Healthy Controls. <i>Gastroenterology</i> , 2017, 152, S714-S715.	0.6	0
223	487 Use of Central Neuromodulators by Gastroenterologists in the Treatment of IBS: A Pilot Survey. <i>American Journal of Gastroenterology</i> , 2019, 114, S282-S282.	0.2	0
224	489 Opioid and Neuromodulator Prescription Patterns Among U.S. Gastroenterologists. <i>American Journal of Gastroenterology</i> , 2019, 114, S283-S283.	0.2	0
225	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0
226	9-Year Evaluation of Temporal Trends in Alosetron Postmarketing Safety Under the Risk Management Program. <i>American Journal of Gastroenterology</i> , 2012, 107, S703-S704.	0.2	0
227	MicroRNA targeting for the therapy of colitis-associated colon cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 571-571.	0.8	0
228	The Effect of Sex and Irritable Bowel Syndrome (IBS) on the Integrated Hypothalamic-Pituitary-Adrenal (HPA) Axis Response to Hormone Challenge. <i>American Journal of Gastroenterology</i> , 2015, 110, S757.	0.2	0
229	The Long Non-Coding RNA AFDN-AS1 Is Expressed in Colonic Epithelial Cells. <i>American Journal of Gastroenterology</i> , 2018, 113, S262-S263.	0.2	0
230	Pain Phenotypes in Chronic Pancreatitis: Beginning to Fine-tune Our Approach to Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .	2.4	0
231	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0